研究单位：[1]Nanfang Hospital, Southern Medical University[2]Hubei Cancer Hospital[3]Hunan Provincial Cancer Hospital[4]Jiangxi Provincial Cancer Hospital[5]Zhejiang Cancer Hospital[6]Anhui Provincial Hospital[7]Huai 'an First People's Hospital[8]Shanghai Zhongshan Hospital[9]Subei people's Hospital[10]The Affiliated Cancer Hospital of Harbin Medical University[11]First Hospital of China Medical University[12]Peking University Cancer Hospital & Institute[13]Tianjin Cancer Hospital[14]Shandong Provincial Cancer Hospital[15]Yunnan Cancer Hospital[16]Sichuan Provincial Cancer Hospital[17]Army Characteristic Medical Center of the People's Liberation Army[18]The First Affiliated Hospital of Henan University of Science and Technology[19]Henan Provincial People's Hospital[20]Shanxi Provincial Cancer Hospital[21]Second Affiliated Hospital of Xi'an Jiaotong University[22]Guangdong Association of Clinical Trials[23]Jiangsu Hansoh Pharmaceutical Co., Ltd.[24]Guangdong Lung cancer institute,Guangzhou,Guangdong,China,510080
This is an open-label, multi-center, randomized, phase III study. It is aimed to firstly evaluate the effectiveness and safety of almonertinib induction therapy in EGFR-mutated patients with unresectable stage III non-small cell lung cancer, and to evaluate the effectiveness and safety of dynamic MRD guided maintenance therapy with almonertinib after induction therapy with almonertinib and local therapy (radical surgery or radiotherapy) evaluated by MDT diagnostic model. The study includes a screening period (not more than 28 days after the subject with signed informed consent before first medication), treatment period (including induction therapy with almonertinib\ radical therapy under MDT model consolidation therapy with almonertinib) and follow-up period.
